USPTO Examiner JOHANSEN PETER N - Art Unit 1644

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18732517Reducing side effects of immunotherapy using genetically modified hematopoietic cellsJune 2024February 2025Allow811YesNo
18658421OX40-Binding Polypeptides and Uses ThereofMay 2024February 2025Allow900NoNo
18605049MRNA THERAPEUTIC COMPOSITIONSMarch 2024August 2024Allow510YesNo
18589536PD-1 Single Domain Antibodies and Therapeutic Compositions ThereofFebruary 2024January 2025Allow1100YesNo
18429213Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigensJanuary 2024June 2025Allow1600YesNo
18418078Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigenJanuary 2024December 2024Allow1111NoNo
18505881MRNA THERAPEUTIC COMPOSITIONSNovember 2023February 2024Allow300YesNo
18486678COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONSOctober 2023April 2025Abandon1802NoNo
18485163ANTI-YELLOW FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USEOctober 2023June 2024Allow800NoNo
18473002ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1September 2023September 2024Allow1210NoNo
18457778DIAGNOSTIC OR PREDICTOR OF RELAPSING REMITTING MULTIPLE SCLEROSISAugust 2023November 2024Allow1511YesNo
18364644THERAPEUTIC AGENT TARGETED TO RECEPTOR PROTEIN, TEST AGENT, ANTIBODY THAT BINDS TO RECEPTOR PROTEIN, AND SCREENING METHOD FOR MOLECULARLY TARGETED DRUGSAugust 2023June 2024Allow1010NoNo
18363672T CELL RECEPTORSAugust 2023August 2024Allow1310NoNo
18354395Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)July 2023April 2025Abandon2121NoNo
18340242SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THE SAME, AND USES THEREOFJune 2023December 2024Allow1821NoNo
18339663T CELL RECEPTORSJune 2023August 2024Allow1410YesNo
18324915Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activityMay 2023September 2024Allow1621NoNo
18318610BISPECIFIC ANTIBODYMay 2023December 2023Allow711YesNo
18310120METHODS, KITS, AND COMPOSITIONS FOR ENHANCING CELLULAR THERAPYMay 2023January 2025Allow2111YesNo
18194105Anti-Coronavirus Antibodies and Methods of UseMarch 2023August 2024Allow1610YesNo
18186730Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered formMarch 2023September 2023Allow601YesNo
18172773ANTI-P53 ANTIBODIESFebruary 2023August 2024Allow1820NoNo
18157632TCR AND PEPTIDESJanuary 2023August 2024Abandon1901NoNo
18151112DYSFUNCTIONAL ANTIGEN-SPECIFIC CD8+ T CELLS IN THE TUMOR MICROENVIRONMENTJanuary 2023October 2024Abandon2211NoNo
18081760Therapeutic Substances, their Preparation and Diagnostic ProcedureDecember 2022June 2024Abandon1801NoNo
18047432METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19October 2022July 2024Allow2031YesNo
18045802ANTI-YELLOW FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USEOctober 2022February 2024Abandon1710NoNo
17932450THERAPEUTIC AGENT TARGETED TO RECEPTOR PROTEIN, TEST AGENT, ANTIBODY THAT BINDS TO RECEPTOR PROTEIN, AND SCREENING METHOD FOR MOLECULARLY TARGETED DRUGSSeptember 2022June 2024Allow2111NoNo
17930867Treatment of Multiple Sclerosis with Anti-CD52 AntibodiesSeptember 2022January 2024Abandon1610NoNo
17929063IMMUNOGENIC COMPOUNDS FOR CANCER THERAPYSeptember 2022April 2024Allow1911NoNo
17820803METHODS FOR DETECTING MULTIPLE SCLEROSIS (MS) DIAGNOSTIC AUTOANTIBODIESAugust 2022August 2024Allow2411YesNo
17820529T CELL RECEPTORSAugust 2022December 2022Allow410NoNo
17799648BISPECIFIC ANTIBODYAugust 2022February 2025Allow3011YesNo
17819401COMBINATION THERAPY TO TREAT BRAIN CANCERAugust 2022March 2025Allow3121YesNo
17818106OX40-Binding Polypeptides and Uses ThereofAugust 2022February 2024Allow1811YesNo
17816550IMMUNOTOXINS, FORMULATIONS THEREOF AND THEIR USE IN MEDICINEAugust 2022April 2025Allow3211NoNo
17812592Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic CancerJuly 2022June 2024Abandon2311NoNo
17812264Chimeric Antigen Receptor-Modified NK-92 CellsJuly 2022April 2024Allow2121YesNo
17843616CHIMERIC ANTIGEN RECEPTORS TARGETING CD70June 2022July 2024Allow2511NoNo
17807473BCMA-BINDING ANTIBODIES AND USES THEREOFJune 2022March 2024Abandon2111NoNo
17824482ANTIBODY COMPOSITIONSMay 2022February 2024Allow2110NoNo
17746645SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPYMay 2022December 2024Allow3121YesNo
17740100ANTI-SIGLEC-5 ANTIBODIES AND METHODS OF USE THEREOFMay 2022January 2024Allow2011YesNo
17694890ANTI-CD40 ANTIBODIES AND USES THEREOFMarch 2022December 2023Allow2111YesNo
17650018MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFFebruary 2022January 2024Allow2321YesNo
17650025MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFFebruary 2022January 2024Allow2321YesNo
17591231ANTI-SIRP ALPHA ANTIBODIESFebruary 2022March 2023Allow1401YesNo
17574152T CELL RECEPTORSJanuary 2022April 2024Allow2721NoNo
17621689SIRPalpha-SILENCED NATURAL KILLER (NK) CELLSDecember 2021April 2025Allow4000YesNo
17557647BISPECIFIC ANTIGEN BINDING MOLECULES COMPRISING ANTI-FAP CLONE 212December 2021August 2024Allow3221NoNo
17549442ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINDecember 2021September 2024Allow3321YesNo
17528103PAR1 MODULATION TO ALTER MYELINATIONNovember 2021August 2023Allow2010NoNo
17524016PD-1 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOFNovember 2021December 2023Allow2511NoNo
17512257ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3)October 2021March 2023Allow1700NoNo
17501200T CELL RECEPTORSOctober 2021April 2023Allow1810YesNo
17501122T CELL RECEPTORSOctober 2021March 2023Allow1710NoNo
17490600MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOFSeptember 2021March 2025Abandon4201NoNo
17489249Antigenic Multimeric Respiratory Syncytial Virus PolypeptidesSeptember 2021June 2025Allow4511NoNo
17475975Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their UsesSeptember 2021October 2023Abandon2511NoNo
17472461IMMUNOTHERAPY METHOD COMPRISING ADMINISTERING A COMBINATION OF IMMUNE EFFECTOR CELLS AND NON-TARGET HEMATOPOIETIC CELLSSeptember 2021June 2022Allow911NoNo
17396033TUMOR CELL VACCINESAugust 2021February 2022Allow601YesNo
17394972T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFAugust 2021April 2025Abandon4401NoNo
17428784Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or DiabetesAugust 2021January 2025Abandon4201NoNo
17383043Reducing Immune Inhibition Induced by SIGLEC-15July 2021July 2023Allow2411NoNo
17421365ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1 (ROR1)July 2021May 2024Allow3500NoNo
17360437MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137June 2021November 2023Allow2930NoNo
17360438MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137June 2021February 2024Allow3221YesYes
17419203CLAUDIN18.2 BINDING MOIETIES AND USES THEREOFJune 2021December 2024Allow4211NoNo
17417896TYPE 1 INTERFERON NEUTRALIZING FC-FUSION PROTEIN AND USE THEREOFJune 2021May 2025Allow4711NoNo
17415284USE OF IL-1BETA BINDING ANTIBODIESJune 2021December 2024Abandon4201NoNo
17348926USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITISJune 2021June 2023Abandon2410NoNo
17328749COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEMYELINATING CONDITIONSMay 2021March 2025Abandon4620NoNo
17214845METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT OF VIRAL OR VIRALLY-INDUCED INFECTIONS AND CONDITIONS, AND ANTI-VIRAL COMPOSITIONS AND THEIR PRODUCTIONMarch 2021July 2024Abandon3921NoNo
17213460IN VIVO USE OF MODIFIED CELLS OF LEUKEMIC ORIGIN FOR ENHANCING THE EFFICACY OF ADOPTIVE CELL THERAPYMarch 2021December 2024Abandon4422NoYes
17210117Antibodies to Programmed Cell Death Protein 1March 2021May 2023Allow2611NoNo
17180200Remnant Tumor Infiltrating Lymphocytes and Methods of Preparing and Using the SameFebruary 2021November 2021Allow921YesNo
17265024MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESFebruary 2021February 2024Abandon3600NoNo
17264948MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYFebruary 2021January 2024Abandon3600NoNo
17265044MUSCLE-TARGETING COMPLEXES AND USES THEREOF IN TREATING MUSCLE ATROPHYFebruary 2021February 2024Abandon3600NoNo
17265019MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIAFebruary 2021January 2024Abandon3600NoNo
17265014MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVAFebruary 2021January 2024Abandon3600NoNo
17265026COMBINATION THERAPIESFebruary 2021October 2024Abandon4501NoNo
17142844BIOMARKERS ASSOCIATED WITH CHECKPOINT IMMUNE THERAPY AND METHODS OF USING SAMEJanuary 2021December 2024Allow4741YesNo
17116588Anti-Coronavirus Antibodies and Methods of UseDecember 2020June 2023Abandon3001NoNo
17103844ANTI-YELLOW FEVER ANTIBODIES, AND METHODS OF THEIR GENERATION AND USENovember 2020June 2022Allow1821YesNo
17083124Engineered Exosomes to Detect and Deplete Pro-Tumorigenic MacrophagesOctober 2020December 2023Abandon3821YesNo
17051160INTERLEUKIN 15 FUSION PROTEINS, AND COMPOSITIONS AND THERAPEUTIC METHODS THEREOFOctober 2020June 2025Allow5621YesNo
17049567SYSTEMS AND METHODS FOR LOCAL MODULATION OF WNT SIGNALINGOctober 2020January 2023Abandon2601NoNo
17046843MODULATION OF IRF-4 AND USES THEREOFOctober 2020September 2024Abandon4721NoNo
17032510SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THE SAME, AND USES THEREOFSeptember 2020March 2023Allow2921YesNo
17024155NK-92 Bone and Brain targetingSeptember 2020June 2023Abandon3311NoNo
17019417METHOD FOR PREVENTING OR TREATING PERIPHERAL ARTERIAL OCCLUSIVE DISEASESeptember 2020July 2024Abandon4631YesNo
16979141CONJUGATE OF ANTIBODY TARGETING BLOOD VESSELS AND PHOTOSENSITIZERSeptember 2020April 2025Abandon5530NoNo
16978067THERAPEUTIC NANOPARTICLES CONTAINING ARGONAUTE FOR MICRORNA DELIVERY AND COMPOSITIONS AND METHODS USING SAMESeptember 2020April 2025Allow5531YesNo
16976869EPSILON TOXIN FROM CLOSTRIDIUM PERFRINGENS AS A VACCINEAugust 2020July 2024Allow4651YesNo
17003925LONG-CHAIN NON-CODING RNA BASED BCL2 GENE INHIBITORAugust 2020January 2025Allow5330NoNo
16999259AMNIOTIC FLUID FORMULATION FOR MODULATING IMMUNE RESPONSESAugust 2020February 2025Abandon5441NoNo
16971925BCMA-BINDING ANTIBODIES AND USES THEREOFAugust 2020March 2022Allow1911NoNo
16994164ANTI-KIT ANTIBODIES AND USES THEREOFAugust 2020September 2023Allow3721NoYes
16991517PROTEASE-RESISTANT NEUROTROPHIC PEPTIDE FOR THE THERAPEUTIC TREATMENT OF NEURODEGENERATIVE AND/OR SKIN DISEASESAugust 2020April 2021Allow810YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JOHANSEN, PETER N..

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.6%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
13
Allowed After Appeal Filing
2
(15.4%)
Not Allowed After Appeal Filing
11
(84.6%)
Filing Benefit Percentile
15.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner JOHANSEN, PETER N. - Prosecution Strategy Guide

Executive Summary

Examiner JOHANSEN, PETER N. works in Art Unit 1644 and has examined 197 patent applications in our dataset. With an allowance rate of 55.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner JOHANSEN, PETER N.'s allowance rate of 55.8% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by JOHANSEN, PETER N. receive 2.08 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by JOHANSEN, PETER N. is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +32.8% benefit to allowance rate for applications examined by JOHANSEN, PETER N.. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.1% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 21.7% of cases where such amendments are filed. This entry rate is in the 20% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 59% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 54.1% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.8% of allowed cases (in the 64% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.